Cytokinetics (NASDAQ:CYTK – Get Free Report) and Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation. Analyst Ratings This is a breakdown of current recommendations […]
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Equities researchers at Cantor Fitzgerald issued their FY2024 EPS estimates for shares of Fulcrum Therapeutics in a note issued to investors on Monday, May 20th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will earn ($0.78) per share for the year. Cantor Fitzgerald currently has a […]
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors bought 9,544 call options on the company. This represents an increase of approximately 867% compared to the typical volume of 987 call options. Fulcrum Therapeutics Stock Down 0.8 % FULC stock opened at $7.64 on […]
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders bought 9,544 call options on the stock. This represents an increase of 867% compared to the average daily volume of 987 call options. Insider Buying and Selling In other Fulcrum Therapeutics news, VP Greg Tourangeau […]
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Leerink Partnrs upped their Q2 2024 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a report released on Monday, May 13th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of $0.74 for the quarter, up from their […]